CORT - Joseph Douglas Lyon Enhances Portfolio With Corcept Therapeutics Stock Options: $79K Acquired | Benzinga
A noteworthy insider acquisition was disclosed on February 14, as Lyon, Chief Accounting Officer at Corcept Therapeutics (NASDAQ:CORT), reported the acquisition of stock options for 150,000 shares.
What Happened: Uncovered in a Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission, Lyon, Chief Accounting Officer at Corcept Therapeutics, executed an insider options move. This move consisted of acquiring stock options for 150,000 shares of CORT, granting Lyon the right to purchase the company's stock at an exercise price of $23.01 per share.
The Wednesday morning update indicates Corcept Therapeutics shares up by 2.13%, currently priced at $23.54. At this value, Lyon's 150,000 shares are worth $79,499.
Delving into Corcept Therapeutics's Background
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Breaking Down Corcept Therapeutics's Financial Performance
Revenue Growth: Corcept Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 21.5%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health ...